Why travel insurance is a must for seniors
Travel insurance can be a huge help to anyone, especially older travelers who may have a greater risk of health issues or unexpected travel disruptions and greater concerns about protecting their finances.
CNBC Select explores why travel insurance is so important for seniors and the policies to consider if you're over 65.
Whether you have private insurance or Medicare, your U.S. health care plan probably isn't valid abroad. That's where your travel insurance policy's medical coverage is invaluable. It will cover the cost of doctor's visits, hospital stays, prescriptions and more. If you need to be flown somewhere for treatment or get back home, a good policy will also cover the cost of medical evacuation.
We recommend buying a policy with at least $100,000 in emergency medical coverage and $250,0000 in evacuation coverage. If you're visiting far-flung locales or are particularly concerned about your health, however, look at policies with higher limits.
Travel Insured International has some of the highest limits we've seen. Plans cover up to $250,000 in emergency medical expenses and $1 million for evacuation or repatriation.
Single-trip and multi-trip/annual policies and cruise insurance. Add-ons include Cancel for Any Reason coverage and a travel inconvenience benefit
Add-on to Worldwide Trip Protector Deluxe or Platinum plan that reimburses 75% of nonrefundable costs when purchased within 21 days of initial trip payment
Available if policy is purchased within 21 days of initial trip deposit.
A standard travel insurance policy won't cover pre-existing conditions if they force you to change your plans or seek medical treatment.
A pre-existing condition is any injury, illness or chronic condition that requires treatment or medication, including diabetes, arthritis, cardiac disease or COPD. If you file a claim, your provider will typically look back 60 to 180 days before you enrolled to see if there were any changes in your medical status.
You can get a pre-existing condition waiver, however, which prevents your insurer from reviewing your records when processing a claim. Many companies offer waivers but require travelers to be medically able to travel and to buy their policy within two weeks of booking. We like Nationwide for its more generous 21-day window in which you can buy coverage and still receive a waiver.
Single- and multi-trip plans and cruise insurance, plus add-ons like CFAR and rental car coverage.
Add-on to Prime plan that reimburses 75% of nonrefundable trip costs if purchased within 21 days of booking (Not available in New York or Washington state)
Available with single-trip plan purchased within 20 days of initial trip deposit (14 days for cruise insurance)
Even if you don't have a medical issue on your trip, you might have to cancel your plans because of a health condition, death in the family or other emergency.
Trip cancellation and interruption coverage are among the best reasons to get travel insurance. A comprehensive plan will reimburse up to 100% of your nonrefundable costs if you need to cancel and up to 150% if you need to cut your trip short.Read your policy's terms to see what events are covered, but common scenarios include:
If you're concerned about your situation being covered or don't want to have to submit proof, a Cancel For Any Reason (CFAR) policy will refund a portion of your expenses, regardless of why you scraped your plans.
Most CFAR plans limit you to 50% to 75% of your nonrefundable costs, but Allianz reimburses 80% of expenses.
Single-trip and multi-trip/annual policies and a rental car plan. OneTrip Prime and Premier plans include coverage for one child 17 or younger when accompanying a covered adult.
Reimburses 80% of nonrefundable trip costs if you cancel at least 48 hours before departure.
Included if policy is purchased within 14 days of initial deposit
Read our review of Allianz Travel Insurance
Cruises are particularly popular with retirees, who enjoy the convenience, entertainment and relaxing atmosphere, and have the funds and free time to devote to an extended excursion.
Viking, Holland America and Cunard all market cruises aimed at older travelers.Cruises come with specific risks, though, including the ship breaking down or you missing your connection. We love Seven Corners' cruise insurance policies, which include up to $250 a day for missed connections, $5,000 for an itinerary change and $250 each time the ship is disabled or misses a port of call. Plus, Seven Corners gives you 20 days to buy a policy with a pre-existing condition waiver and covers travelers up to age 99.
The best way to estimate your costs is to request a quote
Policies provide missed and delayed tour/cruise connection coverage. Cancel for any reason coverage and pre-existing conditions waiver are also available if you buy your plan within the specified time. ***CFAR and IFAR are subject to certain eligibility criteria and are not available in all states
Yes
Many travel insurance companies put age restrictions on their policies, limiting coverage to travelers under 79 or even 65. The cost of a policy can also be much more expensive for older travelers.
Seven Corners will approve coverage for travelers up to age 99 and Faye and Travelex don't have any age restrictions at all.
One single-trip plan with optional add-ons for pet care, adventure sports and damage to vacation rentals
Up to 75% reimbursement of nonrefundable trip costs if purchased within 14 days of initial trip deposit.
Available if policy is purchased within 14 days of initial trip deposit.
Essential, Advantage and Ultimate policies plus last-minute Travel Med Go plan and standalone plans for emergency medical and flight coverage. Upgrades include rental car, pet and adventure activities coverage
Upgrade with Ultimate plan covering 75% of nonrefundable trip costs if purchased within 21 days of initial deposit and 31 days of departure.
Included with Ultimate plan if purchased within 21 days of initial deposit
Travel insurance averages between 4% and 10% of your total nonrefundable trip expenses. Because of increased risk, seniors pay on the higher end of that range.
CNBC Select gathered rate quotes for a 65-year-old traveler and a 30-year-old traveler taking the same one-week $3,000 excursion to London and looking for $250,000 in medical coverage and $1 million in evacuation coverage. While the 30-year-old's rate was about 4.4% of their nonrefundable trip expenses, the 65-year-old was quoted a rate of about 7.3%.
There can be a significant difference in price among carriers, so using a travel insurance marketplace like Squaremouth can help you compare rates in minutes.
SquareMouth is a travel insurance marketplace that allows you can compare top-rated providers, including Berkshire Hathaway, Nationwide, Seven Corners and Tin Leg.
Yes
Read our SquareMouth travel insurance review
The best policy for any traveler depends on your specific needs, the length and location of your excursion and other factors. Our top picks for travel insurance for seniors includes Travel Insured International, Nationwide, Seven Corners, Allianz and Faye.
Some companies allow you to buy a policy up until a day or two before your departure, although enrolling within two weeks of booking ensures you have access to a pre-existing condition waiver and other benefits.
Travel insurance typically costs between 4% and 10% of your nonrefundable trip expenses. For seniors, a policy will more likely be on the higher end of that range. We found coverage for a 65-year-old on a one-week vacation in London was 7.3% of the total expense.
Money matters — so make the most of it. Get expert tips, strategies, news and everything else you need to maximize your money, right to your inbox. Sign up here.
At CNBC Select, our mission is to provide our readers with high-quality service journalism and comprehensive consumer advice so they can make informed decisions with their money. Every travel insurance review is based on rigorous reporting by our team of expert writers and editors with extensive knowledge of travel insurance products. While CNBC Select earns a commission from affiliate partners on many offers and links, we create all our content without input from our commercial team or any outside third parties, and we pride ourselves on our journalistic standards and ethics.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Opinion - With his new prescription drug order, Trump fixes what Biden broke
Americans have been clamoring for sensible prescription drug reform for years. With the stroke of his pen, President Donald Trump answered that call. His executive order aims to bring down drug prices while 'once again putting Americans first.' Luckily, it specifically addresses one of the serious flaws in the Biden administration's Medicare Drug Price Negotiation Program — an oversight that has discouraged investment in affordable, widely used medications. This reform could deliver major savings to patients — without undermining the innovation that drives medical breakthroughs. Now it's up to Congress to finish the job. The reform in question addresses a flaw in the Medicare price-setting scheme put in place by the 2022 Inflation Reduction Act. That law gave the secretary of Health and Human Services sweeping new authority to impose price controls on certain drugs covered by Medicare. But it also drew an arbitrary line between different types of medicines by giving biologics, which are made from living organisms,13 years before price-setting kicks in, while small-molecule drugs, like pills and capsules, get just nine. That four-year gap makes no clinical or economic sense. Many of the most important drugs in history, from aspirin to statins to HIV treatments, are small-molecule medicines. Yet innovators are now steering investment away from them. According to a recent study, investment in small-molecule drugs has already dropped by 68 percent. And compared to pre-IRA levels, new small-molecule cancer drug development programs fell over 40 percent last year. President Trump's order calls for correcting this imbalance. The Republican-backed EPIC Act offers the clearest solution, aligning the treatment of small-molecule drugs with biologics by extending the price-setting window to 13 years. My hope is that this legislation will pass quickly with bipartisan support. Passing EPIC would protect innovation, preserve patient access and deliver on the president's promise to fix what the last administration got wrong. The order also directs the secretary of Labor to write new transparency rules to address some of the other significant issues affecting drug access and prices. That's a big win for patients and a critical step toward restoring fairness to the system and decreasing out-of-pocket costs for Americans. In addition to these transparency reforms, the order acknowledges the critical role of intellectual property rights in bringing new drugs to patients — and promises to optimize those protections in ways that improve access and lower drug costs. Patents and other intellectual property protections play a central role in pushing medical science forward. The previous administration's efforts to undermine these essential tools posed a direct threat to the foundations of America's innovation-driven economy. President Trump's unequivocal stance on this issue should come as welcome news to the nation's inventors and entrepreneurs — including those in the biotech sector. Equally encouraging is the executive order's treatment of the 340B Prescription Drug Program. The program was originally designed to help safety-net providers offer affordable medications to low-income patients. Yet today, less than 40 percent of hospitals that use the program are in underserved areas. During my time in Congress, I took up this issue — championing reforms to promote transparency, increase accountability and require participating hospitals to report patient's benefits. Now, emboldened by the White House, lawmakers should do the same. Altogether, this order is a blueprint for drug pricing reform that's patient-focused, pro-innovation and rooted in real-world solutions. Now, Congress can do its part, beginning with passing the EPIC Act. If they do, American patients could finally get the kind of affordable, innovative and equitable prescription drug sector they've long demanded. Larry Bucshon, MD, a cardiothoracic surgeon, served as the U.S. representative for Indiana's 8th District from 2011 to 2025. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
The Hill
7 hours ago
- The Hill
With his new prescription drug order, Trump fixes what Biden broke
Americans have been clamoring for sensible prescription drug reform for years. With the stroke of his pen, President Donald Trump answered that call. His executive order aims to bring down drug prices while 'once again putting Americans first.' Luckily, it specifically addresses one of the serious flaws in the Biden administration's Medicare Drug Price Negotiation Program — an oversight that has discouraged investment in affordable, widely used medications. This reform could deliver major savings to patients — without undermining the innovation that drives medical breakthroughs. Now it's up to Congress to finish the job. The reform in question addresses a flaw in the Medicare price-setting scheme put in place by the 2022 Inflation Reduction Act. That law gave the secretary of Health and Human Services sweeping new authority to impose price controls on certain drugs covered by Medicare. But it also drew an arbitrary line between different types of medicines by giving biologics, which are made from living organisms,13 years before price-setting kicks in, while small-molecule drugs, like pills and capsules, get just nine. That four-year gap makes no clinical or economic sense. Many of the most important drugs in history, from aspirin to statins to HIV treatments, are small-molecule medicines. Yet innovators are now steering investment away from them. According to a recent study, investment in small-molecule drugs has already dropped by 68 percent. And compared to pre-IRA levels, new small-molecule cancer drug development programs fell over 40 percent last year. President Trump's order calls for correcting this imbalance. The Republican-backed EPIC Act offers the clearest solution, aligning the treatment of small-molecule drugs with biologics by extending the price-setting window to 13 years. My hope is that this legislation will pass quickly with bipartisan support. Passing EPIC would protect innovation, preserve patient access and deliver on the president's promise to fix what the last administration got wrong. The order also directs the secretary of Labor to write new transparency rules to address some of the other significant issues affecting drug access and prices. That's a big win for patients and a critical step toward restoring fairness to the system and decreasing out-of-pocket costs for Americans. In addition to these transparency reforms, the order acknowledges the critical role of intellectual property rights in bringing new drugs to patients — and promises to optimize those protections in ways that improve access and lower drug costs. Patents and other intellectual property protections play a central role in pushing medical science forward. The previous administration's efforts to undermine these essential tools posed a direct threat to the foundations of America's innovation-driven economy. President Trump's unequivocal stance on this issue should come as welcome news to the nation's inventors and entrepreneurs — including those in the biotech sector. Equally encouraging is the executive order's treatment of the 340B Prescription Drug Program. The program was originally designed to help safety-net providers offer affordable medications to low-income patients. Yet today, less than 40 percent of hospitals that use the program are in underserved areas. During my time in Congress, I took up this issue — championing reforms to promote transparency, increase accountability and require participating hospitals to report patient's benefits. Now, emboldened by the White House, lawmakers should do the same. Altogether, this order is a blueprint for drug pricing reform that's patient-focused, pro-innovation and rooted in real-world solutions. Now, Congress can do its part, beginning with passing the EPIC Act. If they do, American patients could finally get the kind of affordable, innovative and equitable prescription drug sector they've long demanded. Larry Bucshon, MD, a cardiothoracic surgeon, served as the U.S. representative for Indiana's 8th District from 2011 to 2025.
Yahoo
10 hours ago
- Yahoo
Not holding Trump officials in contempt? Just one reason not to pass the House budget
The U.S House budget would cost 8.6 million people Medicaid coverage, the Congressional Budget Office reports, and trigger roughly $490 billion in Medicare cuts. Other provisions include: cuts to SNAP and green energy tax credits; a 10-year prohibition on states restricting Artificial Intelligence, and a tax break for purchasing gun silencers. Perhaps most insidiously, the bill makes it difficult for courts to hold administration officials in contempt. Multiple judges are currently considering contempt citations against administration officials. These citations provide a check on executive power. Without them, our president becomes a king. We must let our senators know they must not pass this bill. Helen Wolfson, Durham I applaud the NCDOT trying to be environmentally sensitive when it comes to sourcing the tremendous amount of rock needed to rebuild I-40 through the Pigeon River Gorge. It is also worth mentioning this crisis presents an opportunity to install needed wildlife road crossings along that interstate stretch, as Safe Passage Coalition called for. Enlarging the existing creek culverts to allow bear, deer and elk to cross under the highway would be a triple win: it helps the wildlife survive, it improves motorist safety (hitting a 500-lb bear or 1000-lb elk isn't fun!) and it would also help those culverts and the highway survive hurricanes. Ron Sutherland, chief scientist at Wildlands Network, Durham I've lived in Raleigh, on and off, since 1962. Then, graffiti wasn't much of an issue. For years, the city has had ordinances requiring property owners to clean up graffiti. Today, graffiti and tagging are nearly everywhere, often linked to gangs or people trying to create that impression. Given the wide availability of affordable graffiti removal methods — like soda blasting, which doesn't damage the underlying paint — why doesn't Raleigh invest in mobile cleanup? A city-operated van equipped with eco-friendly cleaning tools, color-matching technology like what's used at Lowe's and a lift cage could make a huge difference. A dedicated employee, perhaps even a police officer for safety, seems like a smart investment. For under $200,000 annually, Raleigh could maintain cleaner streets, support property owners and discourage criminal activity. It's time for Raleigh to be more proactive. A cleaner Raleigh is a safer, more welcoming place. Jarles Alberg, Raleigh The federal debt is a mess. An annual deficit makes paying our debt harder. As a former business owner, we should pay our debt and balance our budget as Congress is attempting. The budget proposal passed by the U.S. House takes a hatchet to clean energy tax credits. Companies rely on these credits to plan for the future, allowing them to create good-paying jobs and build factories, such as the Boviet Solar plant that opened in Pitt County. Toyota announced it will expand its Randolph County plant, investing almost $14 billion. The House budget would eliminate many of the credits these companies relied on to bring investments. This will cause economic uncertainty and could spark divestment in under-invested areas. I served as a Fayetteville councilor for 10 years and am well aware the government must be fiscally responsible. I hope our senators will fight for our communities and keep these jobs and investments safe. Bobby Hurst, Fayetteville Without Medicare, healthcare or food stamps, children will get hungry, sick or, worst, die. Our children are the future of this nation. Without them there's no future. Micheal Wilson, Raleigh Responding to the May 21 op-ed, 'At least 6 NC species face severe threats from new Trump administration proposal,' 28 N.C. native plants are federally listed as endangered in addition to 345 state-listed species, which includes 944 nationally-listed. Rare plants are particularly vulnerable to habitat loss because many only occur in specialized habitats, often overrun by invasive species, or succumb to habitat loss from land conversion. Many animals have some ability to move, but plants do not (outside of seed and/or fruit dispersal), which is further limited in our modern world. Plants create the habitat within which most animals live and are the basis of food chains and webs. Do not ignore the plight of rare flora in what is often an animal-based perspective sometimes referred to as 'plant blindness.' Johnny Randall, former director of conservation at North Carolina Botanical Garden, Chapel Hill
